

IBEX 



TRUSTED 
CANCER
DIAGNOSTICS
FOR ALL

THE GALEN™ PLATFORM

Trusted AI



First Read

**Integrated Diagnostics:
enhanced workflow during case review**

- Improve diagnostic accuracy
- Increase pathologists' productivity and improve lab workflow with AI-powered insights
- Reduce turnaround time
- AI-driven case prioritization, pre-order staining, grading, tumor sizing and more
- Streamline reporting
- Ready for integration with scanning platforms, pathology workflow and lab information software
- Field proven. Deployed worldwide and used in everyday practice


Second Read

**Real Time Quality Control:
safety net for 100% of reported cases**

- Alerts on misdiagnosed and mis-graded cases
- Increase confidence levels and reduce error
- Clinical-grade accuracy
- Field proven. Deployed worldwide and used in everyday practice
- No impact on routine workflows
- Easy to deploy




Cancer heatmap




Gleason heatmap

Reporting tool



Point of interest for quick review



AI-POWERED PATHOLOGY

Clinical Excellence

Breast



Invasive cancer detection
(including rare subtypes):

AUC - 0.990

Sensitivity - 95.5%

Specificity - 93.6%

DCIS detection:

AUC - 0.980

Sensitivity - 93.2%

Specificity - 93.8%

Broad range of detection capabilities:

IDC vs. ILC, DCIS grading, TILs, LVIs,
hyperplasia, inflammation and more

Presented at ECP 2021

Prostate



Cancer vs. benign*:

AUC - 0.991

Sensitivity - 98.4%

Specificity - 97.3%

Pathologists using AI vs. microscope
in primary diagnosis**:

27% reduction in diagnosis time

32% reduction in major discrepancy rate

37% productivity gain

12-24 hours reduction in lab

turnaround time

Going beyond cancer detection*:

G3-4 vs. G5+: AUC - 0.971

G6 vs. G7+: AUC - 0.941

Perineural invasion: AUC - 0.957

*Pantanowitz et al., The Lancet Digital Health,
Aug. 2020

**Presented at USCAP 2021 and ECP 2021

Gastric



Cancer vs. benign:

AUC - 0.994

Sensitivity - 96.7%

Specificity - 97.3%

H. pylori detection:

AUC - 0.966

Sensitivity - 91.4%

Specificity - 91.7%

The only AI solution for the GI tract

Galen Gastric goes beyond cancer detection
and enables detection of lymphomas,
neuroendocrine neoplasms, intestinal
metaplasia, adenoma, LG dysplasia and more

Galen Gastric can drive a more cost-effective
workflow by detecting H.pylori and reducing
turnaround time and stain ordering

Presented at USCAP 2022

Rigorously blinded, multi-site clinical studies. Galen was tested against multiple independent pathologists and on various staining platforms and scanning systems



Ibex Medical Analytics pioneers AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis with clinical-grade AI algorithms and digital workflows that help detect and grade cancer. Our Galen™ platform is deployed worldwide, supporting pathologists, health systems and diagnostic providers in improving the quality and accuracy of diagnosis, implementing comprehensive quality control, reducing turnaround times and boosting productivity with more efficient workflows.

Ibex Medical Analytics

101 Rokach Blvd., Tel Aviv 6153101, Israel

202 Washington St., Brookline, MA 02445



info@ibex-ai.com



www.ibex-ai.com